

EudraCT Database

14 March 2022

Subject:	Results not applicable : trial approved but never started, reason for the premature interruption.
EudraCT Number:	2019-003561-17
Product Name:	TRK-750
Protocol Number:	750CNP01
Title of the Trial:	A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TRK-750 in Colorectal Cancer Patients with Chemotherapy-induced Peripheral Neuropathy Following Oxaliplatin-containing Chemotherapy in the Adjuvant Setting
Sponsor:	Toray Industries, Inc.

Dear Sir/Madam,

On behalf of the Sponsor, Toray Industries, Inc., we would like to inform you of the early termination of the 750CNP01 study worldwide. Sponsor have concluded that the study cannot be conducted due to continuous COVID-19 impacts throughout Europe and is re-considering the development strategy for TRK-750 Project. This decision is not prompted by any safety concerns. You will note that no patient was included on the worldwide level, consequently Clinical Trial Summary Report will not be submitted.

Should you have any queries regarding this notification, please do not hesitate to contact the undersigned.

Sincerely,

Amelia Gheorghisor
Associate I, Global Regulatory Submissions

Fax: +353 12460699

Submissions@labcorp.com;